Cargando…
Transcatheter valvular therapies in patients with left ventricular assist devices
Aortic, mitral and tricuspid valve regurgitation are commonly encountered in patients with continuous-flow left ventricular assist devices (CF-LVADs). These valvular heart conditions either develop prior to CF-LVAD implantation or are induced by the pump itself. They can all have significant detrime...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040555/ https://www.ncbi.nlm.nih.gov/pubmed/36993995 http://dx.doi.org/10.3389/fcvm.2023.1071805 |
_version_ | 1784912499170082816 |
---|---|
author | Dagher, Olina Santaló-Corcoy, Marcel Perrin, Nils Dorval, Jean-François Duggal, Neal Modine, Thomas Ducharme, Anique Lamarche, Yoan Noly, Pierre-Emmanuel Asgar, Anita Ben Ali, Walid |
author_facet | Dagher, Olina Santaló-Corcoy, Marcel Perrin, Nils Dorval, Jean-François Duggal, Neal Modine, Thomas Ducharme, Anique Lamarche, Yoan Noly, Pierre-Emmanuel Asgar, Anita Ben Ali, Walid |
author_sort | Dagher, Olina |
collection | PubMed |
description | Aortic, mitral and tricuspid valve regurgitation are commonly encountered in patients with continuous-flow left ventricular assist devices (CF-LVADs). These valvular heart conditions either develop prior to CF-LVAD implantation or are induced by the pump itself. They can all have significant detrimental effects on patients' survival and quality of life. With the improved durability of CF-LVADs and the overall rise in their volume of implants, an increasing number of patients will likely require a valvular heart intervention at some point during CF-LVAD therapy. However, these patients are often considered poor reoperative candidates. In this context, percutaneous approaches have emerged as an attractive “off-label” option for this patient population. Recent data show promising results, with high device success rates and rapid symptomatic improvements. However, the occurrence of distinct complications such as device migration, valve thrombosis or hemolysis remain of concern. In this review, we will present the pathophysiology of valvular heart disease in the setting of CF-LVAD support to help us understand the underlying rationale of these potential complications. We will then outline the current recommendations for the management of valvular heart disease in patients with CF-LVAD and discuss their limitations. Lastly, we will summarize the evidence related to transcatheter heart valve interventions in this patient population. |
format | Online Article Text |
id | pubmed-10040555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100405552023-03-28 Transcatheter valvular therapies in patients with left ventricular assist devices Dagher, Olina Santaló-Corcoy, Marcel Perrin, Nils Dorval, Jean-François Duggal, Neal Modine, Thomas Ducharme, Anique Lamarche, Yoan Noly, Pierre-Emmanuel Asgar, Anita Ben Ali, Walid Front Cardiovasc Med Cardiovascular Medicine Aortic, mitral and tricuspid valve regurgitation are commonly encountered in patients with continuous-flow left ventricular assist devices (CF-LVADs). These valvular heart conditions either develop prior to CF-LVAD implantation or are induced by the pump itself. They can all have significant detrimental effects on patients' survival and quality of life. With the improved durability of CF-LVADs and the overall rise in their volume of implants, an increasing number of patients will likely require a valvular heart intervention at some point during CF-LVAD therapy. However, these patients are often considered poor reoperative candidates. In this context, percutaneous approaches have emerged as an attractive “off-label” option for this patient population. Recent data show promising results, with high device success rates and rapid symptomatic improvements. However, the occurrence of distinct complications such as device migration, valve thrombosis or hemolysis remain of concern. In this review, we will present the pathophysiology of valvular heart disease in the setting of CF-LVAD support to help us understand the underlying rationale of these potential complications. We will then outline the current recommendations for the management of valvular heart disease in patients with CF-LVAD and discuss their limitations. Lastly, we will summarize the evidence related to transcatheter heart valve interventions in this patient population. Frontiers Media S.A. 2023-03-13 /pmc/articles/PMC10040555/ /pubmed/36993995 http://dx.doi.org/10.3389/fcvm.2023.1071805 Text en © 2023 Dagher, Santaló-Corcoy, Perrin, Dorval, Duggal, Modine, Ducharme, Lamarche, Noly, Asgar and Ben Ali. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Dagher, Olina Santaló-Corcoy, Marcel Perrin, Nils Dorval, Jean-François Duggal, Neal Modine, Thomas Ducharme, Anique Lamarche, Yoan Noly, Pierre-Emmanuel Asgar, Anita Ben Ali, Walid Transcatheter valvular therapies in patients with left ventricular assist devices |
title | Transcatheter valvular therapies in patients with left ventricular assist devices |
title_full | Transcatheter valvular therapies in patients with left ventricular assist devices |
title_fullStr | Transcatheter valvular therapies in patients with left ventricular assist devices |
title_full_unstemmed | Transcatheter valvular therapies in patients with left ventricular assist devices |
title_short | Transcatheter valvular therapies in patients with left ventricular assist devices |
title_sort | transcatheter valvular therapies in patients with left ventricular assist devices |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040555/ https://www.ncbi.nlm.nih.gov/pubmed/36993995 http://dx.doi.org/10.3389/fcvm.2023.1071805 |
work_keys_str_mv | AT dagherolina transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT santalocorcoymarcel transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT perrinnils transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT dorvaljeanfrancois transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT duggalneal transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT modinethomas transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT ducharmeanique transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT lamarcheyoan transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT nolypierreemmanuel transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT asgaranita transcathetervalvulartherapiesinpatientswithleftventricularassistdevices AT benaliwalid transcathetervalvulartherapiesinpatientswithleftventricularassistdevices |